Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Luxturna Model: Spark’s Approach To Retinal Disease Endpoint Embraced In Gene Therapy Guidance

Executive Summary

Established efficacy endpoints may not be suited to assessing gene therapies’ clinically meaningful effects in some rare retinal disorders, US FDA says in draft guidance that gives a shout-out to Spark’s development of a functional vision endpoint for voretigene; guidance also includes recommendations on appropriate control groups and use of sham injections.

Advertisement

Related Content

Reagan-Udall Annual Meeting: 4 Takeaways From US FDA Center Directors
Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA
Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss
Gene Therapy Guidances Will Focus On Specific Diseases, Gottlieb Says
How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss
Spark's Gene Therapy Luxturna Sails Through US FDA Panel

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel